Pancuronium aminosteroid

The γ- cyclodextrin derivative sugammadex (trade name Bridion) has been recently introduced as a novel agent to reverse the action of rocuronium. [4] Sugammadex has been in use since 2009 in many European countries; however, it was turned down for approval twice by the US FDA due to concerns over allergic reactions and bleeding, [5] but finally approved the medication for use during surgical procedures in the United States on December 15, 2015. [6] Neostigmine can also be used as a reversal agent of rocuronium but is not as effective as sugammadex. Neostigmine is often still used due to its low cost compared with sugammadex. [7]

Failure of prompt reversal (within 30 minutes) may occur in the presence of extreme debilitation, carcinomatosis, and with concomitant use of certain broad spectrum antibiotics, or anesthetic agents and other drugs which enhance neuromuscular blockade or cause respiratory depression of their own. Under such circumstances, the management is the same as that of prolonged neuromuscular blockade. Ventilation must be supported by artificial means until the patient has resumed control of his respiration. Prior to the use of reversal agents, reference should be made to the specific package insert of the reversal agent.

Excessive doses of PAVULON® (pancuronium bromide injection) produce enhanced pharmacological effects. Residual neuromuscular blockade beyond the time period needed may occur with PAVULON® (pancuronium bromide injection) as with other neuromuscular blockers. This may be manifested by skeletal muscle weakness, decreased respiratory reserve, low tidal volume, or apnea. A peripheral nerve stimulator may be used to assess the degree of residual neuromuscular blockade and help to differentiate residual neuromuscular blockade from other causes of decreased respiratory reserve.

Pancuronium aminosteroid

pancuronium aminosteroid


pancuronium aminosteroidpancuronium aminosteroidpancuronium aminosteroidpancuronium aminosteroidpancuronium aminosteroid